Indivior PLC (NASDAQ:INDV) Sees Large Increase in Short Interest

Indivior PLC (NASDAQ:INDV) was the target of a large growth in short interest in December. As of December 31st, there was short interest totalling 1,220,000 shares, a growth of 9.9% from the December 15th total of 1,110,000 shares. Based on an average daily volume of 1,280,000 shares, the days-to-cover ratio is presently 1.0 days. Currently, 1.1% of the shares of the stock are short sold.

Analyst Ratings Changes

A number of analysts recently commented on INDV shares. Craig Hallum decreased their price objective on Indivior from $20.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday, October 11th. Piper Sandler reissued an “overweight” rating and set a $16.00 price target (up previously from $15.00) on shares of Indivior in a research report on Friday, October 25th.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Stifel Financial Corp bought a new stake in shares of Indivior during the 3rd quarter worth about $100,000. Bank of New York Mellon Corp acquired a new position in shares of Indivior in the second quarter valued at $188,000. Melqart Asset Management UK Ltd bought a new position in shares of Indivior during the 3rd quarter worth about $132,000. XTX Topco Ltd acquired a new stake in Indivior during the second quarter valued at approximately $249,000. Finally, Jane Street Group LLC acquired a new position in Indivior during the third quarter worth $180,000. Institutional investors and hedge funds own 60.33% of the company’s stock.

Indivior Stock Performance

Shares of Indivior stock traded down $0.01 during trading on Friday, reaching $11.65. The company had a trading volume of 1,060,388 shares, compared to its average volume of 974,047. The company has a market cap of $1.61 billion, a price-to-earnings ratio of -291.18 and a beta of 0.74. The firm’s fifty day moving average is $11.46 and its 200-day moving average is $11.07. Indivior has a fifty-two week low of $7.33 and a fifty-two week high of $23.22.

Indivior (NASDAQ:INDV) last announced its quarterly earnings results on Thursday, October 24th. The company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.15. Indivior had a negative return on equity of 351.08% and a negative net margin of 0.17%. The company had revenue of $307.00 million during the quarter, compared to analyst estimates of $302.25 million. On average, research analysts anticipate that Indivior will post 1.62 EPS for the current fiscal year.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.